查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1832039

2025 年至 2033 年生物樣本庫市場規模、佔有率、趨勢及預測（按樣本類型、生物樣本庫類型、應用、最終用戶和地區分類）

Biobanking Market Size, Share, Trends and Forecast by Specimen Type, Biobank Type, Application, End-User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球生物樣本庫市場規模達643億美元。展望未來， IMARC Group預測，到2033年，該市場規模將達到1,011億美元，2025年至2033年的複合年成長率為5.2%。目前，北美佔據市場主導地位，2024年的市佔率將超過34%。基因組研究活動數量的增加、慢性病盛行率的上升以及對虛擬生物樣本庫的日益關注是推動市場發展的一些關鍵因素。

由於醫學研究和個人化醫療對高品質生物樣本的需求不斷成長，全球生物樣本庫市場正在不斷擴張。基因組學和蛋白​​質組學的進步推動了對保存完好的生物樣本的需求，以支持藥物研發、疾病診斷和生物標記開發。例如，梅奧診所的個人化醫療中心於2024年8月啟動了一項組學策略，整合基因組學、蛋白質組學、代謝組學和微生物組學，以探索基因與環境的相互作用。該計劃致力於推進疾病的預測、診斷和管理，包括癌症和慢性病。該中心旨在利用多基因風險評分和先進的定序技術，提供個人化的醫療保健和創新的治療方案。政府和私人部門對生物樣本庫基礎設施的投資，以及對再生醫學日益成長的關注，進一步推動了市場的發展。此外，自動化樣本管理系統等先進儲存技術的整合，提高了效率和可靠性，從而推動了市場的成長。

人們越來越意識到生物樣本庫在應對癌症和罕見疾病等全球健康挑戰方面的重要性，這對市場產生了重大影響，尤其是在歐洲。採用數位平台進行資料管理和遠端樣本追蹤，確保了更好的可訪問性和透明度。此外，研究機構、製藥公司和生物樣本庫之間的合作正在加速創新，強化了市場在支持臨床研究和治療進步方面的作用。例如，2024 年 4 月，歐洲創新與技術學院 (EIT) 旗下的 EIT Health Scandinavia 推出了 EIT Health 生物樣本庫和健康資料註冊平台。該中心將研究人員、臨床醫生和行業專業人士與歐洲生物樣本庫和資料註冊中心聯繫起來。該平台由 BBMRI-ERIC 開發，簡化了存取流程，提高了樣本利用率，並促進了合作，從而推動醫學研究和創新。

生物銀行市場趨勢：

生物樣本庫在基因組研究和個人化醫療中的作用不斷擴大

目前，隨著基因組研究活動的增多，對生物樣本庫的需求不斷成長，這是支撐市場成長的關鍵因素之一。此外，由於生物樣本庫具有提高生物醫學研究資料可重複性和意義的潛力，全球生物樣本庫數量不斷增加，這也為市場前景提供了積極的訊號。此外，糖尿病、高血壓、癌症、心臟病和呼吸系統疾病等慢性疾病在世界各地人口中的發生率也在上升。世界衛生組織 (WHO) 報告稱，慢性疾病每年導致 4,100 萬人死亡，佔全球死亡人數的 74%。再加上對生物樣本庫的需求不斷成長，以開發能夠有效識別病原體的診斷方法，共同推動了市場的成長。此外，再生醫學、個人化醫療和癌症基因組研究等先進療法的支出不斷增加，為行業投資者提供了豐厚的成長機會。例如，英國生物樣本庫已收集了 50 萬名參與者的基因資料，包括所有參與者的全基因組定序 (WGS)、47 萬人的全外顯子組定序 (WES) 以及 80 萬個變異的基因分型，估計後將變異數擴展到 9,000 萬。此外，臨床實驗室對用於開發基因檢測方法的生物樣本的需求不斷成長，這也對市場產生了積極影響。此外，虛擬生物樣本庫日益受到關注，因為它可以最大限度地減少時間限制、產生高收入，並使研究人員能夠順利進行研究，這也促進了市場的成長。此外，主要參與者正在推出生物樣本庫軟體解決方案，以幫助提高可見度並改善向客戶提供的服務質量，從而加強市場成長。

數位生物銀行解決方案的採用率不斷提高

數位技術的應用正在改變全球生物銀行市場，提高效率並確保更好的資料管理。虛擬生物銀行因其消除地理和物流障礙的能力而越來越受歡迎，為研究人員提供了無縫存取生物樣本和相關資料的途徑。數位平台提高了透明度，實現了即時追蹤並簡化了操作，有助於提高樣本的完整性。例如，2024 年 8 月，Verisense Health, Inc. 推出了 Verisense 數位生物銀行，其中包含來自 100 多萬人的健康資料，預計到 2024 年底將達到 200 萬。它包含來自 570 項研究的資料，並使用人工智慧驅動的資料集編目器來管理和更新資料集。這有助於研究人員更有效地存取、驗證和使用數位健康資料。此外，生物銀行管理軟體的進步使利害關係人能夠最佳化儲存條件、提高合規性並提高營運可擴展性，確保為研究和診斷提供高品質的生物樣本。

慢性病研究中對生物樣本的需求不斷擴大

糖尿病、癌症和心血管疾病等慢性疾病的盛行率不斷上升，推動了對生物樣本的需求，以支持診斷和治療的進步。生物樣本庫透過提供多樣化的生物樣本，在開發早期檢測和治療的創新解決方案方面發揮著至關重要的作用。例如，2024年11月，牛津奈米孔技術公司與英國生物樣本庫合作，開發了首個大規模表觀遺傳資料集，利用先進的DNA/RNA技術對5萬個樣本進行定序。該計畫旨在揭示疾病機制、增強診斷能力並推動個人化治療。透過提供近乎完整的表觀基因組學見解，該計畫支持醫療保健領域的突破，包括早期檢測、個人化干涉以及對疾病進展的深入了解。此外，由於慢性病佔全球死亡人數的大多數，研究機構和製藥公司正在利用生物樣本庫來加速臨床試驗並開發標靶療法。總體而言，這一趨勢凸顯了生物樣本庫在應對全球醫療保健挑戰和改善患者預後的重要性。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球生物樣本庫市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依樣本類型

  • 血液製品
  • 實體組織
  • 細胞系
  • 核酸
  • 其他

第7章：市場區隔：依生物樣本庫類型

  • 基於人群的生物樣本庫
  • 以疾病為導向的生物樣本庫

第 8 章：市場區隔：按應用

  • 療法
  • 研究

第9章：市場區隔：依最終用戶

  • 學術機構
  • 製藥和生物技術公司

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Brooks Automation Inc.
    • Bay Biosciences LLC
    • Boca Biolistics
    • Ctibiotech
    • Cureline Inc.
    • Firalis
    • Greiner Bio-One International GmbH
    • Hamilton Company
    • Merck KGaA
    • ProteoGenex Inc.
    • Thermo Fisher Scientific Inc.
    • VWR Corporation (Avantor Inc.)
Product Code: SR112025A4967

The global biobanking market size was valued at USD 64.3 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 101.1 Billion by 2033, exhibiting a CAGR of 5.2% from 2025-2033. North America currently dominates the market, holding a market share of over 34% in 2024. The rising number of genomic research activities, increasing prevalence of chronic diseases, and rising focus on virtual biobank represent some of the key factors driving the market.

The global biobanking market is expanding due to increased demand for high-quality biological samples in medical research and personalized medicine. Advances in genomics and proteomics are driving the need for well-maintained biospecimens to support drug discovery, disease diagnosis, and biomarker development. For instance, in August 2024, Mayo Clinic's Center for Individualized Medicine launched an omics strategy, integrating genomics, proteomics, metabolomics, and microbiomics to explore gene-environment interactions. This initiative focuses on advancing disease prediction, diagnosis, and management, including cancer and chronic conditions. By utilizing polygenic risk scores and advanced sequencing, the center aims to deliver personalized healthcare and innovative treatment solutions. Government and private investments in biobanking infrastructure and the growing focus on regenerative medicine further boost the market. Additionally, the integration of advanced storage technologies, such as automated sample management systems, enhances efficiency and reliability, fueling market growth.

Rising awareness of the importance of biobanks in combating global health challenges, including cancer and rare diseases, is significantly influencing the market, especially in Europe. The adoption of digital platforms for data management and remote sample tracking ensures better accessibility and transparency. Moreover, collaborations between research institutions, pharmaceutical companies, and biobanks are accelerating innovations, reinforcing the market's role in supporting advancements in clinical research and therapeutics. For instance, in April 2024, EIT Health Scandinavia, part of the European Institute of Innovation and Technology (EIT), introduced the EIT Health Biobanks and Health Data Registries platform. This hub connects researchers, clinicians, and industry professionals with European biobanks and data registries. Developed with BBMRI-ERIC, it simplifies access, boosts sample utilisation, and fosters collaboration to drive medical research and innovation.

Biobanking Market Trends:

Expanding Role of Biobanking in Genomic Research and Personalized Medicine

At present, the rising demand for biobanking due to the increasing number of genomic research activities represents one of the key factors supporting the growth of the market. Besides this, the growing number of biobanks across the globe, due to its potential to enhance the reproductivity and meaning of data generated by biomedical research, is offering a positive market outlook. Additionally, there is a rise in the prevalence of chronic diseases, such as diabetes, hypertension, cancer, heart attack, and respiratory disorders, among the masses around the world. The World Health Organization (WHO) reports that chronic diseases account for 41 Million deaths annually, representing 74% of all global fatalities. This, coupled with the increasing demand for biobanking to develop diagnostics that can effectively identify pathogens, is propelling the growth of the market. Apart from this, the rising expenditure in advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, is offering lucrative growth opportunities to industry investors. For instance, the UK Biobank has collected genetic data from 500,000 participants, including whole genome sequencing (WGS) for all, whole exome sequencing (WES) for 470,000, and genotyping of 800,000 variants, with imputation extending this to 90 Million variants. Moreover, the increasing demand for biospecimens from clinical labs to develop assays for genetic testing is positively influencing the market. In addition, the growing focus on virtual biobank that minimizes time constraints, generates high revenue, and allows researchers to conduct the research smoothly is contributing to the growth of the market. Furthermore, key players are introducing a biobank software solution that assists in gaining visibility and improving the quality of the service provided to customers, which is strengthening the market growth.

Increasing Adoption of Digital Biobanking Solutions

The adoption of digital technologies is transforming the global biobanking market, improving efficiency, and ensuring better data management. Virtual biobanks are gaining traction for their ability to eliminate geographical and logistical barriers, providing researchers seamless access to biospecimens and associated data. Digital platforms enhance transparency, enable real-time tracking, and streamline operations, contributing to better sample integrity. For instance, in August 2024, Verisense Health, Inc. launched the Verisense Digital Biobank, with health data from over one million people, expected to reach two million by the end of 2024. It includes data from 570 studies and uses an AI-powered Dataset Cataloger to manage and update datasets. This helps researchers access, validate, and use digital health data more efficiently. Additionally, advancements in biobank management software are enabling stakeholders to optimize storage conditions, improve compliance, and increase operational scalability, ensuring high-quality biospecimens for research and diagnostics.

Expanding Demand for Biospecimens in Chronic Disease Research

The rising prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular conditions, is fueling demand for biospecimens to support diagnostics and therapeutic advancements. Biobanks play a vital role in developing innovative solutions for early detection and treatment by providing access to diverse biological samples. For instance, in November 2024, Oxford Nanopore Technologies partnered with UK Biobank to develop the first large-scale epigenetic dataset, sequencing 50,000 samples using advanced DNA/RNA technology. This initiative aims to uncover disease mechanisms, enhance diagnostics, and advance personalised treatments. By providing nearly complete epigenome insights, the project supports breakthroughs in healthcare, including early detection, tailored interventions, and improved understanding of disease progression. Moreover, with chronic diseases accounting for the majority of global fatalities, research institutions and pharmaceutical companies are leveraging biobanking to accelerate clinical trials and develop targeted therapies. Collectively, this trend underscores biobanking's importance in addressing global healthcare challenges and enhancing patient outcomes.

Biobanking Industry Segmentation:

Analysis by Specimen Type:

  • Blood Products
  • Solid Tissue
  • Cell Lines
  • Nucleic Acid
  • Others

According to the report, blood products are the leading specimen type in the global biobanking market, owing to their pivotal role in advancing medical research, diagnostics, and therapeutic innovations. Comprising plasma, serum, and whole blood, these samples are integral to studying biomarkers, genetic disorders, and disease mechanisms. Their widespread application in research on chronic conditions such as cancer, cardiovascular diseases, and diabetes highlights their significance. Blood products are also essential for infectious disease studies, aiding in vaccine development and diagnostics. The integration of advanced storage and preservation technologies ensures the integrity and reliability of these specimens, supporting their use in longitudinal and cross-sectional studies. Furthermore, the growing emphasis on precision medicine and genomics has amplified the demand for blood samples, as they enable the development of personalized therapeutic solutions. The expanding global biobanking infrastructure, coupled with collaborations among research institutions and pharmaceutical companies, enhances the accessibility and quality of blood specimens. This strong demand solidifies blood products' position as the dominant specimen type in the global biobanking market, driving innovation and contributing to improved healthcare outcomes.

Analysis by Biobank Type:

  • Population-based Biobanks
  • Disease-oriented Biobanks

According to the report, disease-oriented biobanks dominate the global biobanking market as they provide critical resources for advancing research and treatments focused on specific diseases. These biobanks collect, store, and manage biological samples, such as tissues, blood, and DNA, specifically related to conditions like cancer, cardiovascular diseases, and neurological disorders. Their targeted approach supports precision medicine initiatives by enabling the identification of disease biomarkers, understanding disease mechanisms, and developing tailored therapies. The increasing prevalence of chronic and rare diseases worldwide has amplified the demand for disease-oriented biobanks, driving investments from governments, research institutions, and pharmaceutical companies. Advanced data integration and sample management technologies further enhance their value, enabling seamless sharing of high-quality biospecimens and associated data. These biobanks also play a pivotal role in supporting clinical trials and accelerating the development of innovative diagnostics and treatments. With their focused contribution to global healthcare challenges, disease-oriented biobanks are the cornerstone of modern biobanking, ensuring meaningful progress in disease management and therapeutic advancements.

Analysis by Application:

  • Therapeutics
  • Research

According to the report, research is the leading therapeutics segment in the global biobanking market, driven by the increasing need for high-quality biospecimens to support advancements in medical science and therapeutic innovation. Biobanks are uniquely positioned as the main infrastructures sourcing samples and data for research on diseases and drug discovery and as nuanced repositories of biomarkers to help advance treatment outcomes. Nevertheless, the biobanks with a research orientation have emerged with the growth in precision medicine and genomics because of the maximum importance of developing biomolecules for treatment from the patient's genetic profile. Also, biobanks have the function of responding to the worldwide health problems by contributing to research on the chronic, infectious, and rare genetic diseases. Advancements in sample preservation and handling enhance the application of stored tissues a s useful tools of effective clinical trials and other applications. The relationship between biobanks, research institutions, and pharmaceutical companies enhance the ecosystem and overlays efficiency in discovery of treatments. This firm association with research activities places it as the largest therapeutics segment in the biobanking market, which is facilitating advancements in global healthcare.

Analysis by End-User:

  • Academic Institutions
  • Pharma and Biotech Companies

Pharma and biotech companies lead the market with around 58.3% of market share in 2024. Companies involved in pharma and biotech industries are highly motivated by the utilization of biospecimens in therapeutic products, trials, and precision medicine. These companies rely on biobanks to obtain high quality phenotype samples for biomarker identification, target validation as well as therapeutic validation. The inclusion of biobanking resources into the R&D value chains advances in the timeframe of the preclinical stage and increases productivity in drug development. Due to the trend towards the development of more and more chronic diseases and few occurrences of single diseases, there has been a growing need for various types of biological products, which can improve the methods of treatment for individuals and the technologies for tissue engineering and regeneration. Pharma and biotech firms also benefit from advanced biobank technologies, including automated storage systems and AI-driven data analytics, which enhance sample integrity and optimize utilization. Collaborations with biobanks provide these companies with access to ethically sourced specimens, ensuring compliance with regulatory standards and bolstering their research capabilities. By driving innovation and enabling groundbreaking therapies, pharma and biotech companies play a pivotal role in shaping the global biobanking market and advancing global healthcare solutions.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 34%. The North America region is driven by advanced healthcare infrastructure, significant investments in research and development, and a strong focus on precision medicine. The region benefits from robust biobank networks, supporting large-scale genomic and disease-specific research. Private sector initiatives in association with government funding are further improving the accessibility and quality of biospecimens, thereby forming strong stewardship. Moreover, North America is paying more attention to cutting-edge technologies adoption, including automated biobank management systems and AI-driven analytics. These technologies also improve sample preservation and data integration facilities that validates reliability for research applications. Increase in the incidences of chronic diseases such as cancer, and cardiovascular diseases put more emphasis on the procurement of good quality biospecimens for diagnostics and other therapeutic developments. This creates synergy among various institutions, research centers, and pharmaceutical industries with the result of promoting higher research outcomes of personalized medicine and regenerative options. North America, which continually exhibits a high level of commitment to legal requirements as well as ethics in biobanking, continues to lead in the growth of the worldwide business and its contributions to medical innovation.

Key Regional Takeaways:

United States Biobanking Market Analysis

The US accounted for 84.5% market share in North America. This can be attributed to the rising demand for personalized medicine, advancements in genomics, and increasing government investments in healthcare infrastructure. According to the U.S. Department of Health and Human Services, an estimated 129 Million Americans are affected by at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. This growing prevalence of chronic conditions has heightened the need for biobanks to support research in targeted therapies and precision medicine. Robust funding from institutions such as the National Institutes of Health (NIH) further accelerates biobank development, fostering advancements in genomics and biomedical research. Additionally, the integration of advanced technologies like artificial intelligence (AI) and machine learning enhances the analysis of complex datasets, significantly improving biobank capabilities. Collaboration among private biotech companies, academic institutions, and healthcare organizations strengthens the biobanking ecosystem. Regulatory frameworks, such as the Health Insurance Portability and Accountability Act (HIPAA), ensure secure management and sharing of biological data, instilling trust and encouraging participation. Together, these factors propel the growth of the U.S. biobanking market.

Asia Pacific Biobanking Market Analysis

The biobanking market in the Asia-Pacific (APAC) region is driven by advancements in healthcare infrastructure, increased government investment in research, and growing awareness of personalized medicine. According to the United Nations, China and India account for 18% of the world's population, providing a diverse genetic pool for biobank development. Also, according to the NIH, the 3 major NCDs in the Asia Pacific region are CVDs, cancer and diabetes due to the increasing loss of disability adjusted life years (DALYs). These nations, alongside Japan, play a significant role in advancing genomics research, particularly in cancer and genetic disorders. Expanding healthcare initiatives in countries like India and South Korea, coupled with supportive government policies, further stimulate market growth. International collaborations with global biopharmaceutical companies strengthen biobank capabilities, fostering innovation and research across the region. The combination of population diversity and research focus positions APAC as a key player in the global biobanking landscape.

Europe Biobanking Market Analysis

The European biobanking market is witnessing significant growth, driven by government funding, advancements in biotechnology, and the increasing emphasis on personalized medicine. According to the European Commission, over 35% of the EU population reported a chronic health condition in 2023, including cardiovascular diseases, diabetes, and cancer. This prevalence highlights the need for biobanks to support research and develop targeted therapies for these widespread conditions. Europe's strong healthcare infrastructure, coupled with its collaborative ecosystem of universities, research organizations, and private enterprises, provides a solid foundation for biobank development. Key initiatives, such as the EU's Horizon 2020 programme, have been instrumental in funding large-scale biobank projects focusing on genomics and disease-specific research. The adoption of advanced technologies and analytics further enhances the capabilities of European biobanks in managing and analyzing biological samples. Additionally, the region's stringent regulatory frameworks, including the General Data Protection Regulation (GDPR), ensure the ethical collection, storage, and use of biological data, fostering trust among stakeholders and encouraging public participation. These factors collectively position Europe as a global leader in biobanking, playing a crucial role in advancing medical research, supporting precision medicine, and addressing the growing healthcare challenges associated with chronic diseases.

Latin America Biobanking Market Analysis

The biobanking market in Latin America is driven by rising research investments and a growing focus on chronic disease management. According to the NIH, Brazil alone reported an estimated 928,000 deaths from chronic diseases, highlighting the need for enhanced medical research and biobank support. Governments in countries like Brazil and Mexico are strengthening healthcare infrastructure, creating opportunities for biobank development. Additionally, collaborations with international research institutions and private companies are improving biobank capabilities. While challenges like data management and regulatory frameworks persist, ongoing advancements in these areas are expected to drive further market growth in the region.

Middle East and Africa Biobanking Market Analysis

The Middle East and Africa biobanking market is gaining traction, driven by advancements in healthcare infrastructure and investments in cutting-edge technologies. In the UAE, the Al Jalila Foundation, part of the Mohammed Bin Rashid Al Maktoum Global Initiatives, invested USD 4.6 Million (AED 17 Million) to establish a state-of-the-art robotic biobank in 2022. Developed in collaboration with the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and the Dubai Health Authority (DHA), the biobank will use advanced robotics and artificial intelligence to securely store over seven Million biological samples in cryogenic conditions below -80°C for genetic research. Such initiatives underscore the region's focus on leveraging technology to enhance research capabilities. Additionally, increasing government support and international collaborations further bolster the biobanking landscape in the region, paving the way for significant advancements in medical research and personalized medicine.

Competitive Landscape:

The global biobanking market is competitive, driven by advancements in technology, strategic collaborations, and the growing demand for high-quality biospecimens. Companies are focusing on developing innovative biobank management systems, automated storage solutions, and digital tools to enhance operational efficiency and meet research needs. Collaborative initiatives between biobanks, research organizations, and pharmaceutical firms are fostering innovation in genomic and personalized medicine. For instance, in August 2024, Owkin and Finnish Biobank Cooperative (FINBB) collaborated to advance medical research by applying AI to multimodal patient data. This partnership leverages 11 million biobank samples, biodata, and participant recruitment from Finland's public biobanks. By combining expertise and resources, the initiative aims to accelerate innovative treatments for diseases like inflammatory bowel disease through impactful public-private partnerships. The rise of virtual biobanking and digital platforms is intensifying competition by improving accessibility and scalability. Market players are also emphasizing regulatory compliance, expanding biobank networks, and investing in R&D to address evolving healthcare challenges, further shaping the competitive landscape.

The report provides a comprehensive analysis of the competitive landscape in the keyword market with detailed profiles of all major companies, including:

  • Brooks Automation Inc.
  • Bay Biosciences LLC
  • Boca Biolistics
  • Ctibiotech
  • Cureline Inc.
  • Firalis
  • Greiner Bio-One International GmbH
  • Hamilton Company
  • Merck KGaA
  • ProteoGenex Inc.
  • Thermo Fisher Scientific Inc.
  • VWR Corporation (Avantor Inc.)

Key Questions Answered in This Report

  • 1.What is Biobanking?
  • 2.How big is the biobanking market?
  • 3.What is the expected growth rate of the global biobanking market during 2025-2033?
  • 4.What are the key factors driving the global biobanking market?
  • 5.What is the leading segment of the global biobanking market based on the specimen type?
  • 6.What is the leading segment of the global biobanking market based on the biobank type?
  • 7.What is the leading segment of the global biobanking market based on the application?
  • 8.What is the leading segment of the global biobanking market based on the end-user?
  • 9.What are the key regions in the global biobanking market?
  • 10.Who are the key players/companies in the global biobanking market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biobanking Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Specimen Type

  • 6.1 Blood Products
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Solid Tissue
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cell Lines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Nucleic Acid
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Biobank Type

  • 7.1 Population-based Biobanks
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Disease-oriented Biobanks
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Therapeutics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Academic Institutions
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharma and Biotech Companies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Brooks Automation Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Bay Biosciences LLC
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Boca Biolistics
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Ctibiotech
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Cureline Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Firalis
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Greiner Bio-One International GmbH
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Hamilton Company
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Merck KGaA
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 ProteoGenex Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 VWR Corporation (Avantor Inc.)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Biobanking Market: Major Drivers and Challenges
  • Figure 2: Global: Biobanking Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Biobanking Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Biobanking Market: Breakup by Specimen Type (in %), 2024
  • Figure 5: Global: Biobanking Market: Breakup by Biobank Type (in %), 2024
  • Figure 6: Global: Biobanking Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Biobanking Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Biobanking Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Biobanking (Blood Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Biobanking (Blood Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Biobanking (Solid Tissue) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Biobanking (Solid Tissue) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Biobanking (Cell Lines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Biobanking (Cell Lines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Biobanking (Nucleic Acid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Biobanking (Nucleic Acid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Biobanking (Other Specimen Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Biobanking (Other Specimen Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Biobanking (Population-based Biobanks) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Biobanking (Population-based Biobanks) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Biobanking (Disease-oriented Biobanks) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Biobanking (Disease-oriented Biobanks) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Biobanking (Therapeutics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Biobanking (Therapeutics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Biobanking (Research) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Biobanking (Research) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Biobanking (Academic Institutions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Biobanking (Academic Institutions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Biobanking (Pharma and Biotech Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Biobanking (Pharma and Biotech Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: North America: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: North America: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: United States: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: United States: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Canada: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Canada: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Asia-Pacific: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Asia-Pacific: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: China: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: China: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Japan: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Japan: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: India: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: India: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: South Korea: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: South Korea: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Australia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Australia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Indonesia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Indonesia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Europe: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Europe: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Germany: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Germany: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: France: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: France: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: United Kingdom: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: United Kingdom: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Italy: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Italy: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Spain: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Spain: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Russia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Russia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Latin America: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Latin America: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Brazil: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Brazil: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Mexico: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Mexico: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Middle East and Africa: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Middle East and Africa: Biobanking Market: Breakup by Country (in %), 2024
  • Figure 79: Middle East and Africa: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Global: Biobanking Industry: SWOT Analysis
  • Figure 81: Global: Biobanking Industry: Value Chain Analysis
  • Figure 82: Global: Biobanking Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biobanking Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Biobanking Market Forecast: Breakup by Specimen Type (in Million USD), 2025-2033
  • Table 3: Global: Biobanking Market Forecast: Breakup by Biobank Type (in Million USD), 2025-2033
  • Table 4: Global: Biobanking Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Biobanking Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Biobanking Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Biobanking Market: Competitive Structure
  • Table 8: Global: Biobanking Market: Key Players